Oncogenic driver mutations have been identified in NSCLC including epidermal growth factor receptor gene (EGFR) mutations, anaplastic lymphoma kinase gene (ALK) fusions, v-raf murine sarcoma viral oncogene homolog B (BRAF) mutations, and ROS1 fusions. This evidence concerns the gene BRAF and non-small cell lung carcinoma.